The Royal Society Entrepreneur in Residence (EiR) scheme, part of the Science, aims to increase knowledge and awareness in UK universities of cutting edge industrial science, research and innovation.
The Royal Society EIR scheme provides opportunities for enthusiastic, highly experienced industrial scientists and entrepreneurs to spend one day a week at a university developing a bespoke project to:
- Expose university staff and students to state-of-the-art industrial research and development, and the scientific challenges faced by industry
- Provide support and expert advice aimed at promoting innovation and the translation of research by universities
- Grow confidence in and understanding of business and entrepreneurship among staff and students
- Provide career recognition to the award holders, and support their professional development
TIN Entrepeneurs in Residence:
Dr Stephen Hobbiger, Repurposing TIN
Dr Stephen Hobbiger is the Repurposing TIN's Royal Society Entrepreneur in Residence, providing research guidance and coaching to the UCL Drug Repurposing Community.
Steve is a physician and a former Senior Vice President and Head of Drug Safety and Medical Governance at the Pharmaceutical Company GlaxoSmithKline. He has worked in all phases of clinical trials and is a former Vice President of the Faculty of Pharmaceutical Medicine and he has been part of several cross-Industry bodies including the EU Innovative Medicines Initiative (IMI).
As a Royal Society Entrepreneur in Residence for the Repurposing Therapeutic Innovation Network (TIN), Steve will use his 30+ years of industry experience to help give UCL academics and clinicians an entrepreneurial mindset for accelerating the translation of new indications for existing medicines (Repurposing) as well as advising on the potential of new medicines through working across the other TINs.
A major focus of Steve’s project at UCL TRO will be to build on the enormous potential of Repurposing with the creation of a sustainable multidisciplinary Platform to solicit ideas, help design and secure alternative funding for early phase trials as described in the NHS England Repurposing Roadmap. The second element is to use Steve’s vast experience to teach, coach and mentor those with great scientific ideas who need support navigating the complexities of Drug Development.